The newly formed life science group that resulted from the merger of clinical software vendors XClinical and Fortress Medical with social platform Carenity, announced to rename itself to EvidentIQ Group.
The EvidentIQ offering brings an end-to-end eClinical solution that meets customer demand across clinical operations and clinical data management needs with its suite of applications, including EDC, coding, remote monitoring, RBM ePRO, eTMF, CTMS, RTMS, Payments and eFeasibility within a single integrated cloud platform
Andreas Weber has been appointed CEO of EvidentIQ, leading the group’s strategy and operations. Weber brings in more than 20 years of industry experience and looks back on a career with top management positions at ERT, Bioclinica and Oracle Health Sciences.
“By evolving into a next generation technology amplified data science group, EvidentIQ is paving the way for a new standard in value creation and innovation driven relevance for its customers,” Weber said. “Our customers across XClinical, Carenity and Fortress Medical are at the heart of everything we do. As such, I wanted to assure our current loyal and valued customers, that not only will we continue the existing solutions and support offerings, we will in fact be expanding them technologically as well as increasing their interoperability.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Lewis Baird will take over the sales responsibility as Chief Commercial Officer with EvidentIQ. Before joining EvidentIQ, Baird established and led the European commercial team at Medrio. Prior to Medrio, Baird held commercial leadership roles at DataTrial, Biorasi and Quintiles.
Together with Manuel Neukum (Chief Operations Officer), Michael Chekroun (Chief Strategy and Transformation Officer) and Roland Hiltmann (Chief Financial Officer), Baird is part of Andreas Weber’s Executive Management Team.